Program
Aminolevulinic Acid
Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.
Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | 100 open or running | phase 3since May 7, 2014 | Jun 24, 2008 | none ahead |
| Alpheus Medical | 21 open or running | phase 1since May 2, 2022 | May 2, 2022 | Oct 30, 2027phase 1 · NCT07862647 |
| medac | 20 open or running | phase 3since Oct 18, 2005 | Oct 18, 2005 | none ahead |
| photonamic GmbH & Co. KG | 20 open or running | phase 2since Jul 11, 2018 | Jul 11, 2018 | none ahead |
| Hemerion Therapeutics | 11 open or running | phase 2since Feb 8, 2023 | Feb 8, 2023 | none ahead |
| Lee's Pharmaceutical | 11 open or running | phase 3since Nov 27, 2023 | Nov 27, 2023 | Dec 2027phase 3 · NCT06160492 |
| Neopharma Japan | 10 open or running | phase 2since Jul 12, 2019 | Jul 12, 2019 | none ahead |
| Nobelpharma | 10 open or running | phase 3since Jul 16, 2010 | Jul 16, 2010 | none ahead |
| SBI ALApharma Canada | 10 open or running | phase 3since Mar 22, 2021 | Mar 22, 2021 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | 10 open or running | phase 3since May 12, 2024 | May 12, 2024 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Oct 18, 2005.
- Oct 30, 2014Phase 2 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT02281136 · 29 enrolled · United States
- Jan 22, 2015Phase 2 study in Onychomycosismedac · NCT02355899 · 25 enrolled · Germany
- Dec 7, 20152 phase 2 studies in Keratosis, ActinicSun Pharmaceutical Industries · NCT02628236, NCT02632110
- Jan 13, 2017Phase 3 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT03024060 · United States
- Jul 11, 2018photonamic GmbH & Co. KG’s first study: phase 2 study in Keratosis, ActinicNew to photonamic GmbH & Co. KGphotonamic GmbH & Co. KG · NCT03606122 · 22 enrolled · Germany
- Mar 19, 2019Phase 2 study in Glioblastomaphotonamic GmbH & Co. KG · NCT03897491 · 17 enrolled · Germany
- Jul 12, 2019Neopharma Japan’s first study: phase 2 study in MalariaNew to Neopharma JapanNeopharma Japan · NCT04020653
- Mar 22, 2021SBI ALApharma Canada’s first study: phase 3 study in Breast NeoplasmsNew to SBI ALApharma CanadaSBI ALApharma Canada · NCT04815083 · 57 enrolled · United States
- May 2, 2022Alpheus Medical’s first study: phase 1 study in GliomaNew to Alpheus MedicalAlpheus Medical · NCT05362409 · 22 enrolled · United States
- Feb 8, 2023Hemerion Therapeutics’ first study: phase 2 study in GliomaNew to Hemerion TherapeuticsHemerion Therapeutics · NCT05736406 · 12 enrolled · United States, France
- Nov 27, 2023Lee's Pharmaceutical’s first study: phase 3 study in GliomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT06160492 · 79 planned · China
- May 12, 2024Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 3 study in 5-aminolevulinic AcidNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT06417281 · 86 enrolled · China
- Sep 28, 2026Phase 1 study in GlioblastomaAlpheus Medical · NCT07862647 · 30 planned · United States
- Oct 27, 2026Primary completion moved from 2026-02 to 2027-12Date moved laterphase 3 · +22 months · NCT06160492
Ahead
- Oct 30, 2027Primary completion: phase 1 study in GlioblastomaAlpheus Medical · NCT07862647
- Dec 2027Primary completion: phase 3 study in GliomaLee's Pharmaceutical · NCT06160492
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862647Glioblastoma · United States | 1 | Recruiting | Alpheus Medical | Oct 30, 2027 | 30 |
| NCT064172815-aminolevulinic Acid · China | 3 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Aug 19, 2025 | 86 |
| NCT06160492Glioma · China | 3 | Recruiting | Lee's Pharmaceutical | Dec 2027 | 79 |
| NCT05736406Glioma · United States, France | 2 | Active, not recruiting | Hemerion Therapeutics | Mar 6, 2026 | 12 |
| NCT05362409Glioma · United States | 1 | Completed | Alpheus Medical | Dec 3, 2024 | 22 |
| NCT04815083Breast Neoplasms · United States | 3 | Terminated | SBI ALApharma Canada | Oct 22, 2024 | 57 |
| NCT04020653Malaria | 2 | Withdrawn | Neopharma Japan | May 31, 2020 | 0 |
| NCT03897491Glioblastoma · Germany | 2 | Terminated | photonamic GmbH & Co. KG | Apr 8, 2026 | 17 |
| NCT03606122Keratosis, Actinic · Germany | 2 | Completed | photonamic GmbH & Co. KG | Jul 16, 2019 | 22 |
| NCT03024060Keratosis, Actinic · United States | 3 | Withdrawn | Sun Pharmaceutical Industries | Sep 2017 | 0 |
| NCT02632110Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Sep 12, 2016 | 137 |
| NCT02628236Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | May 2016 | 14 |
| NCT02355899Onychomycosis · Germany | 2 | Completed | medac | Aug 23, 2017 | 25 |
| NCT02281136Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Apr 2015 | 29 |
| NCT02239679Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2016 | 166 |
| NCT02137785Keratosis, Actinic · United States | 3 | Completed | Sun Pharmaceutical Industries | Mar 2015 | 269 |
| NCT01475955Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Nov 2012 | 235 |
| NCT01458587Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2012 | 70 |
| NCT01167322Glioma · Japan | 3 | Completed | Nobelpharma | Dec 2011 | 45 |
| NCT00865878Keratosis, Actinic · United States | 2 | Terminated | Sun Pharmaceutical Industries | Sep 2011 | 6 |
| NCT00706433Acne Vulgaris · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2008 | 266 |
| NCT00241670Brain Neoplasms | 3 | Completed | medac | Jul 2004 | 415 |
How it is read
Names in the registry
- “Aminolevulinic Acid (ALA)”, 3 entries
- “5 Aminolevulinic Acid”, 2 entries
- “PD P 506 A”, 2 entries
- “Aminolevulinic Acid”, 2 entries
- “ALA”, 2 entries
Conditions, from the studies’ own filings
- Keratosis, Actinic, 10 studies
- Glioma, 3 studies
- Glioblastoma, 3 studies
- Breast Neoplasms, 1 study
- Malaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.